Literature DB >> 1948602

Results of resection and proposed guidelines for patient selection in instances of non-colorectal hepatic metastases.

R F Wolf1, J E Goodnight, D E Krag, P D Schneider.   

Abstract

Resection of hepatic metastases from carcinomas of the colon and rectum appears to extend the survival time in appropriately selected patients. Selection criteria have been widely published. Similar data for patients with hepatic metastases from primary sites other than the colon and rectum are lacking. To determine which, if any, patients in the latter category benefit from resections, we reviewed ten such instances treated at our institution plus 141 instances of resection for noncolorectal hepatic metastases previously reported. The over-all five year survival rate after resection of noncolorectal hepatic metastases is 20 per cent. When Wilms' tumor is excluded, the five year survival rate is 15 per cent. Approximately four of ten patients with metastases to the liver from Wilms' tumor or carcinoid survived five years after resection. Similar benefit is rarely obtained after resection of hepatic metastases of the breast, kidney, adrenal gland and carcinomas of the stomach; malignant melanoma, and leiomyosarcoma. No extension of survival is apparent for resection of hepatic metastases of gynecologic malignancies or carcinoma of the pancreas. Specific guidelines for selection are discussed in view of the limited prognosis when tumors other than carcinomas of the colon and rectum metastasize to the liver. Careful patient selection and minimization of complications are required.

Entities:  

Mesh:

Year:  1991        PMID: 1948602

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  10 in total

1.  Surgical resection of recurrent upper abdominal cervical cancer: A case report and review of the literature.

Authors:  Andrea Papadia; Yesenia Moya; Steven E Rodgers; Joseph A Lucci; John P Diaz
Journal:  Gynecol Oncol Case Rep       Date:  2011-10-06

2.  Hepatic metastases from leiomyosarcoma: A single-center experience with 34 liver resections during a 15-year period.

Authors:  H Lang; K T Nussbaum; P Kaudel; N Frühauf; P Flemming; R Raab
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 3.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Results of hepatic resection for sarcoma metastatic to liver.

Authors:  R P DeMatteo; A Shah; Y Fong; W R Jarnagin; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

Review 5.  Surgery for distant melanoma metastasis.

Authors:  Anna M Leung; Danielle M Hari; Donald L Morton
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

6.  Hemostasis after liver resection improves after single application of albumin and argon beam coagulation.

Authors:  Genevieve R Mueller; Ronald F Wolf; Paul D Hansen; Kenton W Gregory; Scott A Prahl
Journal:  J Gastrointest Surg       Date:  2010-07-07       Impact factor: 3.452

Review 7.  Hepatic resection for metastatic endometrioid carcinoma.

Authors:  Brett Knowles; Christopher O C Bellamy; Anca Oniscu; Stephen J Wigmore
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

8.  [Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors].

Authors:  K P Riesener; G Winkeltau; M Klemm; V Schumpelick
Journal:  Langenbecks Arch Chir       Date:  1994

9.  Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma.

Authors:  Johannes Zacherl; Maximilian Zacherl; Christian Scheuba; Rudolf Steininger; Etienne Wenzl; Ferdinand Mühlbacher; Raimund Jakesz; Friedrich Längle
Journal:  J Gastrointest Surg       Date:  2002 Sep-Oct       Impact factor: 3.452

Review 10.  Hepatic resection for noncolorectal nonneuroendocrine metastases.

Authors:  S I Schwartz
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.